Vasylieva I, Smith M, Aravind E, He K, Ling T, Kozel J
bioRxiv. 2025; .
PMID: 40060548
PMC: 11888231.
DOI: 10.1101/2025.02.19.638902.
Logan R, Shelton M, Horan N, Xue X, Maturin L, Eacret D
Res Sq. 2024; .
PMID: 39399686
PMC: 11469374.
DOI: 10.21203/rs.3.rs-5006061/v1.
Xue X, Zong W, Glausier J, Kim S, Shelton M, Phan B
Transl Psychiatry. 2022; 12(1):123.
PMID: 35347109
PMC: 8960783.
DOI: 10.1038/s41398-022-01894-1.
Cole S, Wirkus S
Bull Math Biol. 2022; 84(4):48.
PMID: 35237877
PMC: 8891131.
DOI: 10.1007/s11538-022-01002-w.
Moshontz H, Colmenares A, Fronk G, SantAna S, Wyant K, Wanta S
JMIR Res Protoc. 2021; 10(12):e29563.
PMID: 34559061
PMC: 8693201.
DOI: 10.2196/29563.
Naturalistic follow-up after a trial of medications for opioid use disorder: Medication status, opioid use, and relapse.
Greiner M, Shulman M, Choo T, Scodes J, Pavlicova M, Campbell A
J Subst Abuse Treat. 2021; 131:108447.
PMID: 34098301
PMC: 8556394.
DOI: 10.1016/j.jsat.2021.108447.
Feasibility and Preliminary Efficacy of Isradipine During Outpatient Buprenorphine Stabilization and Detoxification: A Pilot Randomized, Placebo-Controlled Trial.
Kumar N, Mancino M, Thostenson J, McGaugh J, Oliveto A
Subst Abuse. 2020; 14:1178221820970926.
PMID: 33281447
PMC: 7686602.
DOI: 10.1177/1178221820970926.
Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials.
Panlilio L, Stull S, Bertz J, Burgess-Hull A, Kowalczyk W, Phillips K
Psychopharmacology (Berl). 2020; 237(11):3369-3381.
PMID: 32990768
PMC: 7579498.
DOI: 10.1007/s00213-020-05618-5.
An Inverse Relationship Between Alcohol and Heroin Use in Heroin Users Post Detoxification.
Morgan N, Daniels W, Subramaney U
Subst Abuse Rehabil. 2020; 11:1-8.
PMID: 32021548
PMC: 6955608.
DOI: 10.2147/SAR.S228224.
Effect of chemogenetic inhibition of lateral habenula neuronal activity on cocaine- and food-seeking behaviors in the rat.
Nair S, Smirnov D, Estabrook M, Chisholm A, Silva P, Neumaier J
Addict Biol. 2020; 26(1):e12865.
PMID: 31994279
PMC: 10441005.
DOI: 10.1111/adb.12865.
Trajectories of injection drug use among people who use drugs in Vancouver, Canada, 1996-2017: growth mixture modeling using data from prospective cohort studies.
Dong H, Hayashi K, Singer J, Milloy M, DeBeck K, Wood E
Addiction. 2019; 114(12):2173-2186.
PMID: 31328354
PMC: 7498269.
DOI: 10.1111/add.14756.
Free trade and opioid overdose death in the United States.
Dean A, Kimmel S
SSM Popul Health. 2019; 8:100409.
PMID: 31309136
PMC: 6606896.
DOI: 10.1016/j.ssmph.2019.100409.
Anterior Insular Cortex is Critical for the Propensity to Relapse Following Punishment-Imposed Abstinence of Alcohol Seeking.
Campbell E, Flanagan J, Walker L, Hill M, Marchant N, Lawrence A
J Neurosci. 2018; 39(6):1077-1087.
PMID: 30509960
PMC: 6363928.
DOI: 10.1523/JNEUROSCI.1596-18.2018.
Trends in Drug Use-Associated Infective Endocarditis and Heart Valve Surgery, 2007 to 2017: A Study of Statewide Discharge Data.
Schranz A, Fleischauer A, Chu V, Wu L, Rosen D
Ann Intern Med. 2018; 170(1):31-40.
PMID: 30508432
PMC: 6548681.
DOI: 10.7326/M18-2124.
More beds are not the answer: transforming detoxification units into medication induction centers to address the opioid epidemic.
Friedmann P, Suzuki J
Addict Sci Clin Pract. 2017; 12(1):29.
PMID: 29141667
PMC: 5688652.
DOI: 10.1186/s13722-017-0092-y.
Development of a Clinically Viable Heroin Vaccine.
Bremer P, Schlosburg J, Banks M, Steele F, Zhou B, Poklis J
J Am Chem Soc. 2017; 139(25):8601-8611.
PMID: 28574716
PMC: 5612493.
DOI: 10.1021/jacs.7b03334.
Opioid antagonists with minimal sedation for opioid withdrawal.
Gowing L, Ali R, White J
Cochrane Database Syst Rev. 2017; 5:CD002021.
PMID: 28553701
PMC: 6481395.
DOI: 10.1002/14651858.CD002021.pub4.
Relapse to opioid use disorder after inpatient treatment: Protective effect of injection naltrexone.
Nunes E, Gordon M, Friedmann P, Fishman M, Lee J, Chen D
J Subst Abuse Treat. 2017; 85:49-55.
PMID: 28473233
PMC: 5755382.
DOI: 10.1016/j.jsat.2017.04.016.
Buprenorphine for managing opioid withdrawal.
Gowing L, Ali R, White J, Mbewe D
Cochrane Database Syst Rev. 2017; 2:CD002025.
PMID: 28220474
PMC: 6464315.
DOI: 10.1002/14651858.CD002025.pub5.
Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.
Nunes E, Lee J, Sisti D, Segal A, Caplan A, Fishman M
Contemp Clin Trials. 2016; 51:34-43.
PMID: 27687743
PMC: 5466164.
DOI: 10.1016/j.cct.2016.09.006.